Riskpilot← Back to searchSign inGet full accessPHARMA NORD EXPORT ApS
APSActiveCVR 70996510Sadelmagervej 30-32Wholesale of other food · NACE 4638Est. 1982— employees
Revenue 2024
DKK 1,3M
-8% vs 2023
EBITDA margin
-59.6%
-87% vs 2023
Equity ratio
59.7%
Financial strength
Net profit 2024
DKK 6,9M
+9% vs 2023
| Revenue | DKK 1,3M | -8% |
| EBITDA | DKK -794K | -87% |
| Net profit | DKK 6,9M | +9% |
| Total assets | DKK 74,1M | +17% |
| Equity | DKK 44,2M | +18% |
| Employees | — | — |
Legal name
PHARMA NORD EXPORT ApS
CVR number
70996510
Legal form
Anpartsselskab
NACE code
4638 · Wholesale of other food
Founded
19. november 1982
Share capital
DKK 200.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, af den samlede direktion eller af den administrerende
direktør.
Company purpose
Selskabets formål er handel - herunder eksport, import, produktion samt anden i forbindelse hermed stående virksomhed og industri
Address
Sadelmagervej 30-32
Phone
+4575857400
Email
webmaster@pharmanord.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.295 | 2.270 | 1.929 | 2.264 | 2.240 | 1.946 | 2.076 | 1.953 | 2.167 | 1.702 | 1.614 | 1.442 | 1.332 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1.910 | -2.269 | -1.655 | -1.866 | -2.126 |
| EBITDA | 2.295 | 2.270 | 1.929 | 2.264 | 2.240 | 1.946 | 2.076 | 1.953 | 187 | -568 | -41 | -424 | -794 |
| Depreciation & amort. | -0 | -335 | -335 | -335 | -346 | -348 | -363 | -5.056 | -477 | -488 | -488 | -488 | -613 |
| EBIT | 2.295 | 1.935 | 1.594 | 1.929 | 1.894 | 1.598 | 1.713 | -3.103 | -290 | -1.055 | -529 | -912 | -1.407 |
| Net financials | 4.319 | 4.370 | 2.035 | 2.056 | 1.436 | 2.359 | 3.186 | 3.249 | 2.878 | 4.216 | 2.342 | 7.192 | 8.247 |
| Profit before tax | 6.614 | 6.306 | 3.629 | 3.985 | 3.331 | 3.957 | 4.899 | 146 | 2.587 | 3.161 | 1.813 | 6.281 | 6.839 |
| Tax | 620 | 53 | 485 | 830 | 591 | 496 | 627 | 729 | -102 | -13 | -297 | -21 | -50 |
| Net profit | 5.994 | 6.252 | 3.144 | 3.155 | 2.740 | 3.461 | 4.273 | -583 | 2.689 | 3.174 | 2.110 | 6.302 | 6.889 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 67.609 | 77.053 | 74.933 | 78.247 | 77.246 | 80.585 | 84.388 | 94.234 | 74.675 | 73.953 | 66.671 | 63.064 | 74.058 |
| Equity | 47.119 | 53.026 | 56.119 | 59.299 | 62.025 | 65.502 | 69.779 | 73.089 | 40.768 | 43.943 | 46.048 | 37.384 | 44.178 |
| Long-term debt | 6.610 | 10.614 | 10.069 | 9.520 | 8.941 | 8.419 | 7.783 | 7.184 | 6.585 | 11.253 | 10.574 | 10.024 | 9.468 |
| Short-term debt | 8.119 | 8.350 | 3.676 | 4.276 | 1.099 | 1.334 | 1.514 | 6.636 | 20.017 | 11.427 | 3.021 | 8.570 | 13.286 |
| Total debt | 14.729 | 18.965 | 13.745 | 13.796 | 10.040 | 9.754 | 9.297 | 13.820 | 26.603 | 22.680 | 13.596 | 18.593 | 22.754 |
EBITDA margin
-59.6%
This company
15.8%
Market median
-477% vs market
20122024
Equity ratio
59.7%
This company
38.2%
Market median
+56% vs market
20122024
Return on equity
15.6%
This company
18.4%
Market median
+15% vs market
20122024
Net profit margin
517.2%
This company
8.1%
Market median
+6285% vs market
20122024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20122024
Debt / equity
0.68×
This company
0.62×
Market median
+10% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
Mr Audit | Audit | 1982 | — | — |
EW Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2009 | — | — | |
| Board of Directors | 1982 | — | — | |
| Chairman | 2009 | — | — | |
| Board of Directors | 1982 | — | — | |
| Board of Directors | 2009 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PHARMCO II ApS | Company | 50.0% | 50.0% | 2018 |
PharmCo III ApS | Company | 33.3% | 33.3% | 2020 |
| Individual | 33.3% | 33.3% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHARMCO II ApS
PHARMA NORD EXPORT ApS Board members of PHARMA NORD EXPORT ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| MVN revision | Audit | 0 companies |
| Eli Wallin | Chief Executive Officer | 0 companies |
| Claus Hancke | Board of Directors | 0 companies |
| Bernd Schneider | Board of Directors | 0 companies |
| Michael Christiani Havemann | Chairman | 0 companies |
| Hans John Bornemark | Board of Directors | 0 companies |
| Bent Henriksen | Board of Directors | 0 companies |